Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company is developing an intravenous (IV) version of its lead antibiotic, oritavancin, for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection.

Targanta is also developing a number of antibacterial agents currently in pre-clinical development, including an oral version of oritavancin targeting Clostridium difficile-related conditions.










For information on ongoing clinical trials, please visit: www.clinicaltrials.gov